EUCALIA

EUCALIA EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of EUCALIA (286A.T) as of Oct 29, 2026 is 2.37 B JPY. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was 2.29 B JPY — a change of 3.16% (higher).

EBITDA

2.37 BJPY

YoY

3.16%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of EUCALIA is 2025 2.37 B JPY. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of EUCALIA was 2024 2.29 B JPY. It decreases by 3.16% higher compared to the previous year.

The EUCALIA EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2022
865.54 M JPY
Jan 1, 2023
1.90 B JPY
Jan 1, 2024
2.29 B JPY
Jan 1, 2025
2.37 B JPY
The EUCALIA EBITDA history
YEAREBITDAYoY
2.37 BJPY+3.16%
2.29 BJPY+20.69%
1.90 BJPY+119.47%
865.54 MJPY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

EUCALIA Stock analysis

What does EUCALIA do? EUCALIA Inc generates revenue through three core business segments. The Medical Management Comprehensive Support Business offers management consulting, personnel recruitment, DX support, and fundraising for medical corporations. The Senior Related Business provides nursing care facility operations, admission consultation, and facility introduction services. The Highly Controlled Medical Device Business sells contact lenses and supplies pharmaceutical companies with treatment progress data analysis and sales activity support. Subsidiaries contribute through venture investment, brain checkup services, and real estate transactions. Pharmaceutical companies purchase treatment progress data analysis and sales activity support services. Medical corporations utilize management consulting, recruitment, DX, and fundraising support. Nursing care facility operators and potential residents engage with senior care services. Venture investments and real estate transactions are handled by subsidiaries, supporting the company's broader financial ecosystem. The company's revenue streams are diversified across healthcare support, senior care services, and medical device manufacturing. Medical corporations, pharmaceutical firms, and nursing care facility stakeholders form the primary customer base. Subsidiary activities in venture investment and real estate complement the core business model without direct revenue generation from these segments. EUCALIA is one of the most popular companies on Eulerpool.

Frequently Asked Questions about EUCALIA stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of EUCALIA is 2.37 B JPY in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of EUCALIA changed from 2.29 B JPY to 2.37 B JPY, representing a 3.16% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) EUCALIA since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s JPY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s EUCALIA historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — EUCALIA

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — EUCALIA